»ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º ½ÃÀå : ¼­ºñ½º À¯Çüº°, ¿ëµµº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Biologics Fill Finish Services Market, By Service Type, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1515504
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 303 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,466,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,390,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,764,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸®Æ÷Æ® ÇÏÀ̶óÀÌÆ®

»ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 48¾ï 9,454¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â CAGR 7.5%·Î È®´ë

»ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º ½ÃÀå - ½ÃÀå ¿ªÇÐ

»ý¹°ÇÐÀû Á¦Á¦, ¹ÙÀÌ¿À½Ã¹Ð·¯, °³ÀθÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

»ý¹°ÇÐÀû Á¦Á¦, ¹ÙÀÌ¿À½Ã¹Ð·¯, ¸ÂÃãÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â Á¦¾à¾÷°èÀÇ Fill Finish ¼­ºñ½º ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦´Â ¾Ï, ÀÚ°¡¸é¿ªÁúȯ°ú °°Àº º¹ÀâÇÑ Áúº´À» Ä¡·áÇÏ´Â µ¥ È¿°úÀûÀÎ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç, °³¹ß ÆÄÀÌÇÁ¶óÀÎÀº °è¼Ó È®´ëµÇ°í ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ ¹ÙÀÌ¿À½Ã¹Ð·¯´Â »ý¹°ÇÐÀû Á¦Á¦¸¦ ´ëüÇÒ ¼ö ÀÖ´Â ºñ¿ë È¿À²ÀûÀÎ ´ë¾ÈÀ¸·Î °¢±¤¹ÞÀ¸¸ç ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº Á¾¾çÇÐ, ¸é¿ªÇÐ, ½Å°æÇÐ, °¨¿°Çп¡ °ÉÄ£ »ý¹°ÇÐÀû Á¦Á¦µéÀÇ ´Ù¾çÇÑ Ä¡·áÀû ¿ëµµ¿¡ ÀÇÇØ ÁõÆøµÇ°í ÀÖÀ¸¸ç, ¹ÙÀÌ¿À Á¦¾à»çµéÀº ½Å·ÚÇÒ ¼ö ÀÖ°í ȣȯ¼ºÀÌ ³ôÀº ÃæÀü ¸¶°¨ ¼Ö·ç¼ÇÀ» ã°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿¿¡ ±â¹ÝÇÑ Á¢±Ù ¹æ½ÄÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ À¯ÀüÀû, ȯ°æÀû, »ýȰ½À°üÀû ¿äÀο¡ µû¶ó Ä¡·á¸¦ Á¶Á¤ÇÏ´Â ¸ÂÃãÇü ÀÇ·áÀÇ ºÎ»óÀ¸·Î ÀÎÇØ ÇÊÇǴϽ¬ ¼­ºñ½º°¡ Á¦°øÇÏ´Â À¯¿¬Çϰí Á¤¹ÐÇÑ Á¦Á¶ ¿ª·®ÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Ư¼ö »ý¹°ÇÐÀû Á¦Á¦ Ä¡·á¿Í Çõ½ÅÀûÀÎ Ä¡·á Á¢±Ù¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Fill Finish ¼­ºñ½º ½ÃÀåÀº ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

»ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È ¿¬Æò±Õ ¾à 7.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼­ºñ½º À¯Çüº°·Î´Â ¹ÙÀÌ¾Ë ÃæÀü ¼­ºñ½º°¡ 22023³â °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¿ëµµº°·Î´Â »ý¹°ÇÐÀû Á¦Á¦¿Í ¹ÙÀÌ¿À½Ã¹Ð·¯°¡ 2023³â ÁÖ¿ä À¯ÇüÀ̾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ¸ÅÃâ¿¡¼­ ¼±µÎ¸¦ Â÷ÁöÇß½À´Ï´Ù.

»ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¹ÙÀÌ¿ÀÀǾàǰ Fill Finish ¼­ºñ½º ¼¼°è ½ÃÀåÀº ¼­ºñ½º À¯Çü, ¿ëµµ, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº ¼­ºñ½º À¯Çü¿¡ µû¶ó ¾ÚÇÃ ÃæÀü ¼­ºñ½º, ÇÁ¸®ÇÊµå ½Ã¸°Áö ÃæÀü ¼­ºñ½º, ¹ÙÀÌ¾Ë ÃæÀü ¼­ºñ½º, ±âŸ µî 4°¡Áö ¹üÁÖ·Î ºÐ·ùµË´Ï´Ù. ¹ÙÀÌ¾Ë ÃæÀüÀº »ý¹°ÇÐÀû Á¦Á¦ ÃæÀü ¹× ¸¶¹«¸® ¼­ºñ½º ºÐ¾ß¿¡¼­ Á¤Á¡À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ¹ÙÀ̾ËÀÌ ´Ù¾çÇÑ »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ´ëÀÀ·ÂÀÌ ¶Ù¾î³ª±â ¶§¹®ÀÔ´Ï´Ù. ÃʼÒÇü ´Ü¹éÁú ¿ë¾×ºÎÅÍ º¹ÀâÇÑ À¯ÀüÀÚ Ä¡·áÁ¦±îÁö ¹ÙÀ̾ËÀº ÇÕ¸®ÀûÀÎ ºñ¿ëÀ¸·Î ÇÊ¿äÇÑ ±â´ÉÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ´Ù¾çÇÑ Å©±â·Î Á¦°øµË´Ï´Ù. ÀÌ·¯ÇÑ À¯¿¬¼ºÀ» ÅëÇØ Á¦Á¶¾÷ü´Â ¼Ò·® Åõ¿©°¡ ÇÊ¿äÇÑ Ãʱâ ÀÓ»ó½ÃÇèºÎÅÍ º»°ÝÀûÀÎ »ó¾÷ »ý»ê¿¡ À̸£±â±îÁö ¸ðµç °³¹ß ´Ü°èÀÇ ¹ÙÀ̾ËÀ» È¿À²ÀûÀ¸·Î ä¿ï ¼ö ÀÖ½À´Ï´Ù. ÀǾàǰ¿¡ ¹ÙÀ̾ËÀ» »ç¿ëÇÏ´Â °ÍÀº ¿À·£ ¼º°øÀÇ ¿ª»ç¸¦ °¡Áö°í ÀÖ½À´Ï´Ù. ¹ÙÀ̾˿¡ ´ëÇÑ È®¸³µÈ ÃæÀü ±â¼ú°ú ǰÁú°ü¸® ÀýÂ÷°¡ Á¸ÀçÇÏ¿© ÀϰüµÇ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â »ý»êÀ» º¸ÀåÇÕ´Ï´Ù.

½ÃÀåÀº ¿ëµµ¿¡ µû¶ó ¹é½Å, »ý¹°ÇÐÀû Á¦Á¦ ¹× ¹ÙÀÌ¿À½Ã¹Ð·¯, ±âŸ ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦ ¹× ¹ÙÀÌ¿À½Ã¹Ð·¯´Â Ä¡·á ¸ñÀûÀ¸·Î »ç¿ëµÇ´Â ±¤¹üÀ§ÇÑ »ý¹°ÇÐÀû Á¦Á¦¸¦ Æ÷ÇÔÇÕ´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦´Â ´Ü¹éÁú, Ç×ü, À¯ÀüÀÚ µî »ý¹°Ã¼ ¶Ç´Â ±× Á¦Ç°¿¡¼­ ÃßÃâÇÑ ÀǾàǰÀÔ´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀº ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, ¸¸¼ºÁúȯ µî ´Ù¾çÇÑ Áúº´ Ä¡·á¿¡ »ç¿ëµË´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯´Â ½ÂÀÎµÈ ±âÁ¸ »ý¹°ÇÐÀû Á¦Á¦ÀÇ °íµµ·Î À¯»çÇÑ ¹öÀüÀÌÁö¸¸ µ¿ÀÏÇÑ »çº»Àº ¾Æ´Õ´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀº ¿À¸®Áö³Î »ý¹°ÇÐÀû Á¦Á¦¸¦ ´ëüÇÒ ¼ö ÀÖ´Â º¸´Ù ÇÕ¸®ÀûÀÎ °¡°ÝÀÇ ÀǾàǰÀÔ´Ï´Ù.

»ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º ½ÃÀå - Áö¿ªÀû ÀλçÀÌÆ®

Áö¿ªº° ½ÃÀå ¿ìÀ§: ¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ Fill Finish ¼­ºñ½º ½ÃÀå¿¡¼­ ºÏ¹Ì°¡ Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ¸¹Àº ¹ÙÀÌ¿À Á¦¾à»ç, źźÇÑ ÀÇ·á ÀÎÇÁ¶ó, ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØ µîÀÌ Áö¿øµÇ°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÌ Áö¿ªÀº Á¦Ç° ǰÁú°ú ±ÔÁ¦ ¿ä°Ç(FDA) Áؼö¸¦ º¸ÀåÇϱâ À§ÇØ Ã·´Ü ÃæÀü ¸¶°¨ ±â¼ú°ú ÀÚµ¿È­ ½Ã½ºÅÛÀ» µµÀÔÇÏ´Â µ¥ ¾ÕÀå¼­°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ °­Á¡Àº »ý¹°ÇÐÀû Á¦Á¦ ÃæÀü ¹× ¸¶°¨ ¼­ºñ½º¸¦ Àü¹®À¸·Î ÇÏ´Â ´ëÇü À§Å¹°³¹ß ¹× Á¦Á¶¼öʱâ°ü(CDMO)ÀÌ ÁýÁߵǾî ÀÖÀ¸¸ç, ´õ¿í °­È­µÇ°í ÀÖ½À´Ï´Ù. À̵é CDMO´Â ¹ÙÀÌ¾Ë ÃæÀü, ÇÁ¸®ÇÊµå ½Ã¸°Áö ¹× ±âŸ »ý¹°ÇÐÀû Á¦Á¦ÀÇ Æ¯¼öÇÑ ¿ä±¸»çÇ׿¡ ¸Â´Â Ư¼ö Æ÷Àå ¼Ö·ç¼Ç µî Á¾ÇÕÀûÀÎ ±â´ÉÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ÃÖ±Ù µ¿ÇâÀ¸·Î´Â ÄÚ¾îÆÄ¸¶(Core Pharma)°¡ °³¹ß ¹× Á¦Á¶ ¿ª·®À» È®´ëÇϱâ À§ÇØ µÎ °³ÀÇ cGMP ½Ã¼³À» »õ·Î µµÀÔÇÑ °ÍÀ» µé ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿òÁ÷ÀÓÀº ´ºÀúÁö ÁÖ¿¡ ±â¹ÝÀ» µÐ ÀÌ È¸»ç°¡ À§Å¹°³¹ß ¹× Á¦Á¶¼öʱâ°ü(CDMO) ºÐ¾ß¿¡¼­ ºü¸£°Ô ¼ºÀåÇϰí ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù.

»ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º ½ÃÀå - °æÀï»óȲ :

º£¸µ°ÅÀΰÖÇÏÀÓ, ijÅÍ·±Æ®, ·ÐÀÚ ±×·ì, È­ÀÌÀÚ ¼¾ÅÍ¿ø, ¿ì½Ã ¹ÙÀÌ¿À·ÎÁ÷½º´Â Ź¿ùÇÑ ÃæÁø ¼­ºñ½º Á¦°øÀ¸·Î ¹ÙÀÌ¿À Á¦¾à¾÷°èÀÇ ¸®´õ·Î ÀÎÁ¤¹Þ°í ÀÖ½À´Ï´Ù. º£¸µ°ÅÀΰÖÇÏÀÓÀº ±¤¹üÀ§ÇÑ ¼¼°è ÀÔÁö¿Í Á¾ÇÕÀûÀÎ »ý¹°ÇÐÀû Á¦Á¦ Á¦Á¶ ¿ª·®À» °®Ãß°í ÀÖÀ¸¸ç, ¿©±â¿¡´Â ÇÊÇÇ´Ï½Ì ¾÷¹«¿¡ ´ëÇÑ Àü¹® Áö½Äµµ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ijÅÍ·±Æ®´Â ÷´Ü Àü´Þ ±â¼ú°ú Àü ¼¼°è¿¡ °ÉÄ£ źźÇÑ ½Ã¼³ ³×Æ®¿öÅ©¸¦ ÅëÇØ »ý¹°ÇÐÀû Á¦Á¦¸¦ À§ÇÑ ½Å·ÚÇÒ ¼ö ÀÖ°í È®Àå °¡´ÉÇÑ ÃæÀü ¹× ¸¶°¨ ¼Ö·ç¼ÇÀ» º¸ÀåÇÕ´Ï´Ù. ·ÐÀÚ ±×·ìÀº ¿£µå Åõ ¿£µå ¹ÙÀÌ¿ÀÀǾàǰ Á¦Á¶ ¼­ºñ½º·Î Àß ¾Ë·ÁÁ® ÀÖÀ¸¸ç, º¹ÀâÇÑ »ý¹°ÇÐÀû Á¦Á¦ ¹× ´ë±Ô¸ð »ý»ê¿¡ ´ëÇÑ ´ëÀÀ·ÂÀÌ ¶Ù¾î³ª¸ç, Pfizer CentreOneÀº ¸ÂÃãÇü Á¦Á¶ ¼Ö·ç¼ÇÀ» Á¦°øÇϰí ÃæÀü ¸¶°¨ ¼­ºñ½ºÀÇ Ç°Áú°ú Çõ½Å¼ºÀ¸·Î ³ôÀº Æò°¡¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ³ôÀº Æò°¡¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ±Þ¼ÓÇÑ »ç¾÷ È®Àå°ú ±â¼ú·ÂÀ¸·Î À¯¸íÇÑ ¿ì½Ã ¹ÙÀÌ¿À·ÎÁ÷½º´Â ÇÊÇÇ´Ï½Ì °øÁ¤¿¡ ƯȭµÈ Àü¹®¼ºÀ» Æ÷ÇÔÇØ Á¾ÇÕÀûÀÎ »ý¹°ÇÐÀû Á¦Á¦ Á¦Á¶ ¿ª·®À» Á¦°øÇÕ´Ï´Ù. dzºÎÇÑ ¾÷°è °æÇè, ±â¼ú Çõ½Å ¹× ±ÔÁ¦ Áؼö¸¦ °áÇÕÇÏ¿© ½Å·ÚÇÒ ¼ö ÀÖ´Â ÃæÀü ¹× ¸¶°¨ ¼Ö·ç¼ÇÀ» ¿øÇÏ´Â Àü ¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ °í°´ÀÇ ´Ù¾çÇÑ ¿ä±¸¿¡ ºÎÀÀÇϰí ÀÖ½À´Ï´Ù.

°æÀïÀº ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ÀÇ Á¦ÈÞ¸¦ ÅëÇØ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 6¿ù, Bora Pharmaceuticals CorporationÀº ¸Þ¸±·£µå ÁÖ º¼Æ¼¸ð¾î Ä·µç¿¡ À§Ä¡ÇÑ Emergent BioSolutionsÀÇ ¹«±Õ Á¦Á¶ ½Ã¼³°ú ´ë±Ô¸ð »ó¾÷Àû È®ÀåÀÇ ÀÏȯÀ¸·Î ÇÕÀÇ¿¡ ¼º°øÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå »ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå »ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå »ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º »ê¾÷ Á¶»ç

Á¦5Àå »ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º ½ÃÀå : COVID-19 ¿µÇ⠺м®

Á¦6Àå »ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º ½ÃÀå ±¸µµ

Á¦7Àå »ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º ½ÃÀå - ¼­ºñ½º À¯Çüº°

Á¦8Àå »ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º ½ÃÀå - ¿ëµµº°

Á¦9Àå »ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º ½ÃÀå - Áö¿ªº°

Á¦10Àå ÁÖ¿ä º¥´õ ºÐ¼® - »ý¹°Á¦Á¦ Fill Finish ¼­ºñ½º ¾÷°è

Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Biologics Fill Finish Services Market size was valued at USD 4,894.54 Million in 2023, expanding at a CAGR of 7.5% from 2024 to 2032.

Biologics fill-finish is the final stage of manufacturing a biologic drug product. Biologics are drugs produced from living organisms or their products, such as proteins, antibodies, and vaccines. Fill-finish refers to the process of filling a sterile drug product into vials, syringes, or cartridges and then sealing and labeling the containers. The fill-finish process is complex and requires a high degree of expertise to ensure that the product is sterile, safe, and effective.

Biologics Fill Finish Services Market- Market Dynamics

Growing Demand for Biologics, Biosimilars, and Personalized Medicine Drives Market Growth

The growing demand for biologics, biosimilars, and personalized medicine is a driving force behind the growth of fill finish services in the pharmaceutical industry. Biologic drugs, known for their efficacy in treating complex diseases such as cancer and autoimmune disorders, continue to expand their development pipelines. Simultaneously, biosimilars are gaining traction as cost-effective alternatives to biologics, further stimulating market growth. This growth is amplified by the diverse therapeutic applications of biologics across oncology, immunology, neurology, and infectious diseases, prompting biopharmaceutical companies to seek reliable and compliant fill finish solutions. In 2020, approximately 60% of new drug approvals by the FDA were considered to have some form of biomarker-based approach, a key component of precision medicine. Moreover, the rise of personalized medicine, which tailors treatment based on genetic, environmental, and lifestyle factors, necessitates flexible and precise manufacturing capabilities provided by fill finish services. As a result, the market for fill finish services is poised to thrive amidst increasing demand for specialized biologic therapies and innovative treatment approaches.

Biologics Fill Finish Services Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.5% over the forecast period (2024-2032)

Based on Service Type segmentation, Vial Filling Services was predicted to show maximum market share in the year 2023

Based on Application segmentation, Biologics and Biosimilars were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Biologics Fill Finish Services Market- Segmentation Analysis:

The Global Biologics Fill Finish Services Market is segmented based on Service Type, Application, and Region.

The market is divided into four categories based on Service Type: Ampoule Filling Services, Prefilled Syringes Filling Services, Vial Filling Services, and Others. Vial filling reigns supreme in the world of biologics fill-finish services. That's because Vials excel at accommodating a wide range of biologics. From minuscule protein solutions to complex gene therapies, vials offer the necessary functionality at a reasonable cost. They come in a vast array of sizes. This flexibility allows manufacturers to efficiently fill vials for any stage of development, from early-stage clinical trials requiring small doses to full-scale commercial production. The use of vials in pharmaceuticals has a long and successful history. Well-established filling techniques and quality control procedures exist for vials, ensuring consistent and reliable production.

The market is divided into three categories based on Application: Vaccines, Biologics and Biosimilar, and Others. Biologics and Biosimilars encompass a broader range of biological products used for therapeutic purposes. Biologics are drugs derived from living organisms or their byproducts, such as proteins, antibodies, and genes. They can be used to treat a variety of conditions, including cancer, autoimmune diseases, and chronic illnesses. Biosimilars are highly similar versions of existing, approved biologics, but not identical copies. Biosimilars offer a more affordable alternative to the original biologics.

Biologics Fill Finish Services Market- Geographical Insights

Geographically, Market Dominance: North America holds a significant share in the global Biologics Fill Finish Services market. This is attributed to the presence of many biopharmaceutical companies, robust healthcare infrastructure, and stringent regulatory standards. The region leads in adopting advanced fill finish technologies and automation systems to ensure product quality and compliance with regulatory requirements (FDA). The region's prominence is further enhanced by a concentration of leading Contract Development and Manufacturing Organizations (CDMOs) specializing in biologics fill finish services. These CDMOs offer comprehensive capabilities, including vial filling, prefilled syringes, and other specialized packaging solutions tailored to the specific needs of biologic drugs. One recent development in this area can be CorePharma's expansion in its development and manufacturing capacities with the incorporation of two new cGMP facilities, this move highlights the New Jersey-based company's rapid growth in the Contract Development and Manufacturing Organization (CDMO) sector.

Biologics Fill Finish Services Market- Competitive Landscape:

Biol Boehringer Ingelheim, Catalent, Lonza Group, Pfizer CentreOne, and WuXi Biologics are recognized leaders in the biopharmaceutical industry for their exceptional fill-finish services. Boehringer Ingelheim stands out with its extensive global presence and comprehensive biologic manufacturing capabilities, including specialized expertise in fill-finish operations. Catalent offers advanced delivery technologies and a robust network of facilities worldwide, ensuring reliable and scalable fill-finish solutions for biologic drugs. Lonza Group is renowned for its end-to-end biopharmaceutical manufacturing services, excelling in handling complex biologics and large-scale production. Pfizer CentreOne provides customized manufacturing solutions and maintains a strong reputation for quality and innovation in fill-finish services. WuXi Biologics, known for its rapid expansion and technological prowess, offers comprehensive biologics manufacturing capabilities, including specialized expertise in fill-finish processes. These companies combine extensive industry experience, technological innovation, and regulatory compliance to meet the diverse needs of biopharmaceutical clients seeking reliable fill-finish solutions globally.

The competition is further propelled by business collaboration in diverse fields. For instance, In June 2024 Bora Pharmaceuticals Co., Ltd. announced that it had successfully agreed with Emergent BioSolutions' sterile manufacturing facility in Baltimore-Camden, Maryland as part of a major commercial expansion for the Company.

Recent Developments:

In May 2024, Argonaut Manufacturing Services, a contract development and manufacturing organization (CDMO) specializing in biopharma and life sciences, secured $45 million in funding to bolster its new facility for drug product fill/finish in Carlsbad, CA.

In May 2024, PCI Pharma Services, a worldwide contract development and manufacturing organization (CDMO), plans to showcase its newly integrated robotics technology for sterile fill-finish operations at its San Diego facility during BIO 2024 in San Diego.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOLOGICS FILL FINISH SERVICES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Aenova

Ajinomoto Bio-Pharma Services

Akron Biotech

Baxter BioPharma Solutions

Boehringer Ingelheim

Bushu Pharmaceuticals

Cognate BioServices

Emergent BioSolutions

Fresenius Kabi

Jubilant HollisterStier

Novasep

Pfizer CentreOne

Seikagaku

Symbiosis Pharmaceutical Services

WuXi Biologics

GLOBAL BIOLOGICS FILL FINISH SERVICES MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL BIOLOGICS FILL FINISH SERVICES MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL BIOLOGICS FILL FINISH SERVICES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Biologics Fill Finish Services Market Overview

2. Executive Summary

3. Biologics Fill Finish Services Key Market Trends

4. Biologics Fill Finish Services Industry Study

5. Biologics Fill Finish Services Market: COVID-19 Impact Analysis

6. Biologics Fill Finish Services Market Landscape

7. Biologics Fill Finish Services Market - By Service Type

8. Biologics Fill Finish Services Market - By Application

9. Biologics Fill Finish Services Market- By Geography

10. Key Vendor Analysis- Biologics Fill Finish Services Industry

11. 360 Degree Analyst View

12. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â